期刊
NATURE REVIEWS DRUG DISCOVERY
卷 12, 期 5, 页码 388-404出版社
NATURE PORTFOLIO
DOI: 10.1038/nrd4001
关键词
-
资金
- European Community's Seventh Framework Programme [260872]
- Medical Research Council, UK
- European Union FP7
- European Developing Countries Clinical Trials Partnership
- National Institutes for Health Research (NIHR) University College London (UCL) Hospitals NHS Trust Biomedical Research Centre
- UBS Optimus Foundation, Switzerland
- National Institutes of Health through National Institute of Allergy and Infectious Diseases [1R01AI104589]
- Centers for Disease Control and Prevention TB Trials Consortium
- Bill and Melinda Gates Foundation
Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development, including an update of ongoing TB treatment trials, newer clinical trial designs, TB biomarkers and adjunct host-directed therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据